Lymphoma

Second-line therapy with axicabtagene ciloleucel induced a complete metabolic response in 71% of adults with relapsed or refractory large B-cell lymphoma ineligible for autologous stem cell transplant, results of a phase 2 study showed.

Relative risk for venous thromboembolism appeared high among patients with COVID-19 and cancer who received specific cancer treatments, according to study results published in JAMA Oncology.

The addition of metformin to standard chemotherapy improved outcomes for patients with diffuse large B-cell lymphoma, according to findings presented at Society of Hematologic Oncology Annual Meeting.

An infusion of lisocabtagene maraleucel induced deep and durable responses among most adults with relapsed or refractory follicular lymphoma, according to results of the phase 2 TRANSCEND FL trial.

CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated high-risk diffuse large B-cell lymphoma and double-hit or triple-hit lymphoma, according to research presented at ASCO Annual Meeting.

CHICAGO — Loncastuximab tesirine and polatuzumab vedotin may show improved efficacy and manageable toxicity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, according to research presented at ASCO Annual Meeting.

CHICAGO — Researchers presented the maximum dose for indenoisoquinoline LMP744 during the ASCO Annual Meeting, reporting prolonged stability in select patients.

CHICAGO — In this video, Emanuele Zucca, MD, discusses the IELSG37 trial supporting the omission of mediastinal radiotherapy in patients with primary mediastinal B-cell lymphoma who achieve complete metabolic response after chemotherapy.

Christopher Flowers, MD, has been appointed division head of cancer medicine at The University of Texas MD Anderson Cancer Center.

CHICAGO – In this Healio video exclusive, Christopher Flowers, MD, discusses how the combination of zanubrutinib and obinutuzumab vs. obinutuzumab alone leads to longer PFS in patients with relapsed/refractory follicular lymphoma.